LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%
Wed, 20th Jan 2021 17:40
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Alliance Pharma PLC - healthcare company - Expects see-through revenue for 2020 to be down 5% on the prior year at GBP137.5 million from GBP144.3 million reported for 2019, both on a reported basis and on a constant currency basis, reflecting the impact of the Covid-19 pandemic. Underlying pretax profit for 2020 is expected to be marginally ahead of market expectations. "As we progress into 2021, we look forward to regaining the strong momentum and revenue growth of recent years, and to benefiting from the additional growth opportunities that Amberen brings into the group," said Chief Executive Peter Butterfield. The acquisition of Biogix has brought Amberen into Alliance Pharma, a brand for the relief of menopause symptoms. The acquisition creates scale in the company's business in the US and is expected to be earnings enhancing in 2021 and significantly earnings enhancing from 2022.